ERBB2 and breast cancer: This includes a global phase Ib study of CYH33 in combination with olaparib in advanced solid tumors (NCT04586335) and a phase Ib study of CYH33 in combination with endocrine therapy with or without palbociclib in patients with HR+, HER2− advanced breast cancer (NCT04856371).